A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.
by on Monday, May 21st, 2012 | No Comments
Condition: Hormone Receptor Positive Breast Cancer
Interventions: Drug: faslodex 500mg; Drug: arimidex 1mg; Drug: faslodex dummy; Drug: arimidex dummy
Sponsors: AstraZeneca; AstraZeneca
Not yet recruiting – verified May 2012